International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationRole of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis
Introduction
Carcinoma of unknown primary (CUP) is a heterogeneous group of cancers in which regional or distant metastases are detected with no identifiable primary tumor (1). Because CUP represents metastatic disease, the initial treatment in most patients is chemotherapy (1). Unfortunately, in spite of significant improvements in tumor characterization 2, 3, staging 4, 5, and patient selection 6, 7, chemotherapy alone is not curative in most cases 8, 9, 10, 11, 12. However, in some patient subsets, the combination of chemotherapy and definitive local therapy can be curative 1, 13. These subsets include patients with metastases to the cervical 14, 15, 16, 17 or axillary lymph nodes 18, 19 and isolated metastases to the brain (20). These conditions are characterized by limited overall disease burden and a disease location that is amenable to definitive local therapy.
CUP in the soft tissue and lymph nodes of the abdomen and pelvis is generally considered be incurable. Some investigators have argued that aggressive local therapy is not indicated in these cases because, believing that metastases in these locations indicate widely disseminated disease (21). However, modern imaging (4) and pathologic evaluation 2, 3 techniques have allowed us to more accurately stage and characterize CUP (5). Further, modern conformal radiation therapy techniques have allowed us to deliver definitive radiation therapy to areas of the abdomen and pelvis while sparing surrounding normal tissues 22, 23, 24, 25, 26, 27. However, whether definitive local therapy for CUP in the abdomen and pelvis is beneficial is unknown. Therefore, the goal of this study was to determine whether radiation therapy was effective in CUP in the modern era, as measured by survival rates, local disease control, and toxicity.
Section snippets
Patients and Methods
After approval from our institution’s Internal Review Board, patients were identified through a search of the University of Texas M.D. Anderson Cancer Center Department of Radiation Oncology databases. In all, 381 patients with CUP were identified who were treated with radiation between 2002 and 2009. Of these, 40 patients were treated to metastatic sites in the soft tissues or nodal basins of the abdomen and/pelvis. Three of these patients had putative primary disease sites identified during
Cohort characteristics
The characteristics of the 37 patients in this study are shown in Table 1. Ten (27%) were men, and 27 (73%) were women, with a median age of 55 years (range, 37–74 years). In 21 patients (57%), disease was limited to the nodal basins of the abdomen and pelvis. Ten patients (27%) had disease in the nodal basins of the abdomen and pelvis and had evidence of metastasis outside the abdomen and pelvis. Six patients (16%) had disease in the soft tissues of the abdomen and pelvis (pelvic side wall [n
Discussion
CUP of the abdomen and pelvis is a heterogeneous group of tumors with no standard treatment approach and a poor overall prognosis. In this study, we found that definitive local therapy resulted in long-term disease control in patients with localized CUP involving the soft tissues and lymph node basins of the abdomen and pelvis.
The importance of locoregional disease control in CUP has been demonstrated in multiple disease sites 14, 15, 16, 17, 18, 19, 20. The best characterized sites of CUP
References (32)
- et al.
Overview of patient management and future directions in unknown primary carcinoma
Semin Oncol
(2009) - et al.
Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary
J Clin Oncol
(2008) - et al.
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation
J Clin Oncol
(2008) - et al.
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site
Cancer
(2007) - et al.
Diagnostic strategies for unknown primary cancer
Cancer
(2004) - et al.
Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma
Clin Cancer Res
(1999) - et al.
Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site
J Clin Oncol
(2002) - et al.
5-fluorouracil, Adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary
J Clin Oncol
(1986) - et al.
Carcinoma of unknown primary site
Cancer
(2000) - et al.
Taxane-based chemotherapy for patients with carcinoma of unknown primary site
Cancer J
(2001)
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: The Minnie Pearl Cancer Research Network
J Clin Oncol
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site
Cancer
Treatment for patients with unknown primary cancer and favorable prognostic factors
Semin Oncol
Guidelines for radiotherapeutic techniques for cervical metastases from an unknown primary
Int J Radiat Oncol Biol Phys
Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: Results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation
Int J Radiat Oncol Biol Phys
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure
Int J Radiat Oncol Biol Phys
Cited by (3)
Three cases of women with HPV-related squamous cell carcinoma of unknown primary in the pelvis and retroperitoneum: A case series
2016, Gynecologic Oncology ReportsCitation Excerpt :Similarly, in the series from MDACC, women treated with chemoradiation were alive with or without disease for an average of 22 months (range 6–48 months) (Table 2) (Clements et al., 2010). Larger series of a more diverse group of patients with unknown primaries of the abdomen and pelvis have also shown survival benefits using definitive radiotherapy (Kelly et al., 2012). In this series, each woman presented with hip pain and was found to have large volume disease in the pelvis and retroperitoneum.
Carcinoma of unknown primary in the inguinal lymph node region of squamous cell origin: A case series
2014, Practical Radiation OncologyCitation Excerpt :Two courses of chemotherapy were given as induction chemotherapy that could reduce tumor bulk prior to concurrent chemoradiation and reduce the risk of distant metastasis. Kelly et al10 reported that locoregional radiation therapy is crucial for inguinal region CUP of squamous cell origin as CUP of the inguinal region generally behaves as locally advanced disease. All of our patients received a radical course of radiation therapy.
CUP - Medical treatment in specific subgroups
2013, Onkologe
Conflict of interest: none.